This Pre-Solicitation opportunity from Department Of Health And Human Services was posted on July 16, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

synthesis of prodrug analogs and cyclopentane peptide nucleic acid (PNA) precursors

Closed

75N98026Q00819CREAGENINCFederal

Submission Closed07/05/2026, 01:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

Federal

Vivo Efficacy of Blood stable Thiobenzamides 

Solicitation # 75N98026Q01123

Solicitation 75N98026Q01123 is a combined synopsis and solicitation issued by the National Institutes of Health Office of the Director under the Department of Health and Human Services. The contract seeks the procurement of services to evaluate the vivo efficacy of blood stable Thiobenzamides. The scope of work encompasses the use of mouse disease models, BSL-3 viral load monitoring, immunophenotyping, and comprehensive project management. This acquisition is structured as a Firm-Fixed-Price contract for commercial items in accordance with FAR 12.6, falling under NAICS code 325414. The performance of the contract is centered in Bethesda, Maryland. Interested parties must submit their responses by the deadline of September 20, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

ACAN Vaccinia Immunoglobulin intravenous (human) - VIGIV

Solicitation # WS5872093541

Public Services and Procurement Canada, acting on behalf of the Public Health Agency of Canada, has issued an Advanced Contract Award Notice for the procurement of Vaccinia Immunoglobulin intravenous (human), known as VIGIV. This medical product is required to protect against complications arising from vaccinations with live-replicating smallpox vaccines containing the vaccinia virus. The government intends to negotiate a contract with Emergent BioSolutions Canada Inc, provided no other qualified suppliers express interest. The solicitation, identified by number WS5872093541, was posted on September 10, 2026, with a response deadline of September 30, 2026. Other potential suppliers may submit a statement of capabilities by this date to challenge the pre-identified award. The contract is managed by the Department of Public Works and Government Services for performance within Canada.

Department of Public Works and Government Services

POSTED

DEADLINE

Bio-Hazardous Tissue Transport ServicesThis subcontract for Bio-Hazardous Tissue Transport Services supports NIH NIMH research projects by providing specialized transportation of post-mortem brain tissue. The contractor is responsible for the rapid transit of biological specimens from hospitals and medical examiners to the NIH facility within a 150-mile radius of Bethesda. All transport must utilize refrigerated vehicles and temperature-monitoring devices to ensure specimen integrity. The service provider must strictly adhere to OSHA biosafety standards for bio-hazard containment and DOT hazardous materials regulations. This opportunity is managed by the National Institutes of Health Olao under the Department of Health and Human Services, with a response deadline of September 11, 2026.

National Institutes Of Health Olao

POSTED

DEADLINE

Specialty Medical Consumables SupplyThe Specialty Medical Consumables Supply subcontract, issued by the Southern Regional Health Authority under the Government of Jamaica, facilitates the procurement of essential medical supplies. This agreement focuses on the provision of specialized items, including surgical drapes, sterile kits, catheters, and various infection control products. The primary purpose of this contract is to ensure a continuous supply of these critical materials in instances where the demand exceeds the existing inventory held by the prime contractor. Classified under NAICS code 325414, which pertains to pharmaceutical and medical manufacturing, this subcontract is designed to maintain operational readiness within the regional health system. The contract was officially posted on August 22, 2026, and serves as a strategic mechanism to mitigate supply chain risks by providing a secondary source for high-demand medical consumables. Interested parties can access further details and procurement documentation through the official electronic procurement portal provided by the government.

Southern Regional Health Authority

POSTED

DEADLINE

Medical Diagnostic Test Kit SupplyThe Defense Logistics Agency under the Department of Defense has issued a subcontract for the supply of 100 E. coli detection test kits. These diagnostic kits must strictly adhere to FDA regulations, specific shelf-life requirements, and Department of Defense medical packaging standards to ensure quality and viability. Classified under NAICS code 325414, this procurement focuses on the delivery of specialized medical diagnostic tools. The contract was posted on August 11, 2026, and is managed through the DLA's acquisition systems to support military medical readiness.

Defense Logistics Agency

POSTED

DEADLINE

Medical Supply Procurement – Petrolatum GauzeThis subcontract with the Defense Logistics Agency under the Department of Defense involves the manufacture or supply of 27 units of petrolatum gauze, identified by NSN 6510-01-112-6414. The procurement falls under NAICS code 325414 and requires all units to meet strict military medical standards. Key delivery requirements include a minimum shelf life of 36 months, with a mandate that the time elapsed from manufacture to delivery does not exceed five months. The contract was posted on August 10, 2026.

Defense Logistics Agency

POSTED

DEADLINE

Typhoid Vi Polysaccharide Vaccine SupplyThis subcontract through the Defense Logistics Agency under the Department of Defense involves the supply of 1,000 units of FDA-compliant, preserved Typhoid Vi Polysaccharide Vaccine. The procurement is categorized under NAICS code 325414 and is designated for delivery to a U.S. Navy vessel. The agreement is established under FOB Destination terms, ensuring the delivery of the medical supplies to the specified naval location. The contract was posted on August 10, 2026, and is managed via the DIBBS system.

Defense Logistics Agency

POSTED

DEADLINE

Supply and Delivery of Typhoid VI Polysaccharide Vaccine (NSN 6505015334962)This subcontract with the Defense Logistics Agency involves the procurement, packaging, and delivery of 1,000 units of preservative-free Typhoid VI Polysaccharide Vaccine. The product must comply with NDC 49281-0790-51 and NSN 6505015334962. The vaccines are to be delivered to the USS Theodore Roosevelt (CVN 71) at FPO AP 96632 by August 10, 2026. Shipping must be handled via FOB Destination using fast and traceable methods to ensure secure arrival.

Defense Logistics Agency

POSTED

DEADLINE

MMR Vaccine Supply and Delivery

Defense Logistics Agency

POSTED

DEADLINE

Pharmaceutical Product Supply – Aluminum Hydroxide Gel

Defense Logistics Agency

POSTED

DEADLINE

Measles, Mumps, and Rubella (MMR) Vaccine Supply and DeliveryThe contract entails the supply and delivery of three units of Measles, Mumps, and Rubella vaccine to a U.S. Navy vessel at a forward operating base destination, with strict requirements for traceable express shipping and full compliance with established medical handling standards. The contractor is responsible for ensuring the vaccines remain viable throughout transit by adhering to temperature control, packaging, and documentation protocols mandated for biological materials. This is a subcontract under the Department of Defense, managed by the Defense Logistics Agency, with a NAICS code of 325414 indicating pharmaceutical preparation manufacturing. The delivery must be completed in accordance with military logistics guidelines, and all shipping records must maintain a verifiable chain of custody from origin to final receipt aboard the vessel. The contract was posted on August 9, 2026, and the place of performance is tied to a military operational location, though specific geographic details are not provided. The award reference number SPE2DX25D8022 and delivery identifier SPE2D926F8119 are linked to the official DLA procurement system, underscoring the mission-critical nature of timely and secure delivery. While the solicitation number is not listed, the subcontract structure suggests coordination with a prime contractor to fulfill the DOD’s medical readiness requirements. All activities must comply with federal regulations governing vaccine distribution and military supply chain integrity.

Defense Logistics Agency

POSTED

DEADLINE

Supply of Tetanus and Diphtheria Toxoids, Adsorbed Vaccine

Defense Logistics Agency

POSTED

about 1 month ago

DEADLINE

N/A

AI Contract Overview

The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is seeking a contractor to support the synthesis and characterization of advanced prodrug analogs and cyclopentane peptide nucleic acid precursors for use in preclinical research targeting cancer and HIV. These materials, derived from sulfanylbenzamide and peptide nucleic acid chemistries, are not commercially available and require specialized synthetic expertise to produce at scales sufficient for biological evaluation. The contractor will be responsible for scale-up, custom synthesis, purification, and full characterization of optimized lead compounds to enable ongoing studies aimed at evaluating therapeutic activity, refining lead candidates, and advancing the most promising candidates toward potential clinical development. The solicitation, designated as 75N98026Q00819CREAGENINC, was posted on July 16, 2026, with a response deadline of July 5, 2026, indicating an error in dates as the response deadline precedes the posting date. The contract falls under NAICS code 325414 for pharmaceutical and medicine manufacturing and is not subject to any small business set-asides. The work will be performed at the Laboratory of Bioorganic Chemistry in Bethesda, Maryland, with primary point of contact being Vishnuvajjala Hanumanth Rao of the NIH Office of Laboratory Science and Safety. The materials produced will serve as critical inputs for preclinical evaluation and are foundational to future therapeutic development programs focused on anti-cancer and anti-HIV applications.

General Info

Contractor to synthesize and characterize advanced prodrug analogs and PNA precursors for cancer and HIV preclinical research.

Agency

Department Of Health And Human Services → National Institutes Of Health OlaoView Agency

NAICS

325414 - Biological Product (except Diagnostic) ManufacturingView NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(1)

Notice+of+Intent+-+VISHNU++CREAGEN+INC.docx

DOCX

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed

Response DeadlineJul 5

Deadline has passed

PostedJul 16

Presolicitation

Submission Closed

07/05/2026, 01:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao

Contacts1 person available

OfficeBETHESDA, MD, 20892, USA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health Olao

View Agency Profile

Office AddressBETHESDA, MD, 20892, USA

Contacts

Vishnuvajjala Hanumanth Rao

contact@example.gov

Full Description

Background Information: The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports biomedical research to improve the understanding, prevention, and treatment of diseases affecting human health. 

  Within the Laboratory of Bioorganic Chemistry, the Synthetic Bioactive Molecules Section conducts research focused on the discovery and development of novel therapeutic compounds for the treatment and prevention of cancer and HIV infection. Ongoing studies have identified several promising sulfanylbenzamide-derived compounds and cyclopentane peptide nucleic acid precursor materials with potential applications as anti-cancer therapeutics, HIV prevention and treatment agents, and diagnostic technologies. 

  To support these research efforts, the Synthetic Bioactive Molecules Section requires synthesis scale-up, custom synthesis, purification, and characterization of optimized lead compounds and specialized precursor materials. These materials are not commercially available and require specialized synthetic expertise and production capabilities to generate quantities sufficient for continued preclinical evaluation. 

The materials produced under this requirement will be used in ongoing preclinical studies to evaluate compound activity, optimize lead candidates, and support advancement toward future clinical development. 